EANS-Adhoc: SYGNIS Pharma AG
SYGNIS Pharma AG announces changes in Management
Board
17.10.2012 – 09:57
-------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- C.E.O. Interviews 17.10.2012 SYGNIS Pharma AG announces changes in Management Board Heidelberg, 17 October 2012 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) announced today that Dr. Frank Rathgeb, Co-CEO/CMO will resign from his office in the Management Board of the company by October 31, 2012 in mutual agreement with the Supervisory Board. The retirement of Dr. Rathgeb takes place in context with the intended strategic reorientation of the company after the planned contribution of all shares of X-Pol Biotech, S.L., into SYGNIS Pharma AG, with the consequence that drug development and research in the field of therapeutics will no longer be in the core focus of the company. Ende of adhoc Further inquiry note: Michael Wolf Telefon: +49 (6221) 454 - 6 E-Mail: Michael.Wolf@sygnis.de end of announcement euro adhoc -------------------------------------------------------------------------------- issuer: SYGNIS Pharma AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 (0)6221 454-6 FAX: +49 (0)6221 454-777 mail: contact@sygnis.de WWW: http://www.sygnis.de sector: Biotechnology ISIN: DE000A1E9B74 indexes: CDAX, Prime All Share stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf, Stuttgart, regulated dealing/prime standard: Frankfurt language: English